Clinical trials: Patients With Tumor
Anemia
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies
- Trial name
- NCT06737081
- Testing
- SAL-0951 tablets 4mg, SAL-0951 tablets 5mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Multiple Myeloma
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy.
- Trial name
- NCT01242930
- Testing
- Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Geron Corporation
Carcinoma, Hepatocellular
PI-88 in Hepatocellular Carcinoma After Hepatectomy
The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.
- Trial name
- NCT00247728
- Testing
- PI-88
- Where
- 6 sites in Taiwan
- Volunteers
- 172 people
- Sponsor
- Cellxpert Biotechnology Corp.
Advanced Solid Tumor
Study to Assess AFM24 in Advanced Solid Cancers
AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has…
- Trial name
- NCT04259450
- Testing
- 14 mg AFM24, 40 mg AFM24, 80 mg AFM24
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 85 people
- Sponsor
- Affimed GmbH
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasms, Respiratory Tract Neoplasms
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
This Expanded Access Program will provide access of taletrectinib therapy to patients with locally advanced or metastatic ROS1-positive NSCLC who are not an appropriate candidate for an approved therapy, for any ongoing…
- Conditions
- Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site
- Trial name
- Tale EAP (NCT06841874)
- Testing
- Taletrectinib
- Sponsor
- Nuvation Bio Inc.
Lung Malignancy
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
Artificial intelligence (AI) based algorithms have demonstrated increased accuracy in predicting the risk of Lung Cancer among patients with an incidental pulmonary nodule (IPN) on chest radiographs.
- Trial name
- CREATE (NCT05817110)
- Testing
- Participant Cohort
- Where
- 22 sites in Egypt, India and 3 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Hodgkin's Lymphoma
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
MGCD0103 is an experimental drug that belongs to a class of drugs known as the histone deacetylase inhibitors, which may restore normal control in cancer cells by affecting the genes and proteins that are being made.
- Trial name
- NCT00358982
- Testing
- MGCD0103
- Where
- 5 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Mirati Therapeutics Inc.
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Multiple Myeloma
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in…
- Trial name
- NCT01850524
- Testing
- Ixazomib, Dexamethasone, Lenalidomide
- Where
- 147 sites in United States, Belgium and 5 more
- Volunteers
- 705 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine.
- Trial name
- SEATTLE (NCT05954780)
- Testing
- Selinexor
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- iOMEDICO AG
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
- Trial name
- NCT03237325
- Testing
- SGX942
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 266 people
- Sponsor
- Soligenix
Prostate Cancer
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate…
- Trial name
- OPTYX (NCT05467176)
- Testing
- Relugolix
- Where
- 96 sites in United States
- Volunteers
- 999 people
- Sponsor
- Sumitomo Pharma America, Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Triple Negative Breast Cancer
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of camrelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy in participants…
- Trial name
- NCT04613674
- Testing
- Camrelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 441 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Neoplasms
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
This multi-center, open-label, non-randomized, non-placebo-controlled, Phase I study will define the safety profile and tumor response profile of the multi-kinase inhibitor BAY73-4506 as oral treatment in combination with the…
- Trial name
- NCT00934882
- Testing
- Regorafenib (BAY73-4506)
- Where
- 7 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Bayer
Cholangiocarcinoma
Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. It is the second-most common liver cancer, after hepatocellular carcinoma (HCC).
- Trial name
- cholangio (NCT03042182)
- Testing
- Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
- Where
- 2 sites in Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Multiple Myeloma
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Primary Objective: To determine if Multi Myeloma (MM) patients mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 6 x 10^6…
- Trial name
- NCT02221479
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, Follicular, Non-Hodgkin Lymphoma
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with…
- Trial name
- NCT01164696
- Testing
- [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.